Syverson Strege & Co’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Syverson Strege & Co’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3	Closed	-$13	–	664
2023 Q1	$13	Hold	3	–	–	﹤0.01%	666
2022 Q4	$18	Hold	3	–	–	﹤0.01%	319
2022 Q3	$0	Hold	3	–	–	﹤0.01%	348
2022 Q2	$0	Hold	3	–	–	﹤0.01%	359
2022 Q1	$0	Hold	3	–	–	﹤0.01%	342
2021 Q4	$0	Hold	3	–	–	﹤0.01%	504
2021 Q3	$0	Hold	3	–	–	﹤0.01%	483
2021 Q2	$0	Hold	3	–	–	﹤0.01%	304
2021 Q1	$0	Hold	3	–	–	﹤0.01%	293
2020 Q4	$0	Buy	+3	New	+$10	﹤0.01%	261

Other funds holding CTIC

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Syverson Strege & Co's CTIC Position: Q2 2023 in Review

Syverson Strege & Co sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 3 shares — an estimated $13 sold.

Syverson Strege & Co first reported a position in CTIC in Q4 2020 and held it in 10 quarters. The position peaked at $18 in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Syverson Strege & Co reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Syverson Strege & Co sold 3 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $13.
Syverson Strege & Co first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2020 and held it in 10 quarters.
Syverson Strege & Co's CTI BioPharma Corp. (DE) Common Stock position peaked at $18 in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.